U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H25N3O2S2
Molecular Weight 391.551
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FONAZINE

SMILES

CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)S(=O)(=O)N(C)C)N(C)C

InChI

InChIKey=VWNWVCJGUMZDIU-UHFFFAOYSA-N
InChI=1S/C19H25N3O2S2/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5/h6-12,14H,13H2,1-5H3

HIDE SMILES / InChI
Molecular Formula C19H25N3O2S2
Molecular Weight 391.551
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including, https://www.jstage.jst.go.jp/article/gnam1977/3/2/3_113/_pdf, http://www.ncbi.nlm.nih.gov/pubmed/8564192

Fonzine (also known as dimetotiazine) is an analgesics and anti-inflammatory agent marketed in Japan and Europe under the name Migristene and indicated for the treatment of migraine and headaches secondary to other disease. Fonzine exerts its activity by inhibiting serotonin and histamine H1 receptors.

CNS Activity

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Histamine H1 receptor
315
Target ID: P35367
Gene ID: 3269.0
Gene Symbol: HRH1
Target Organism: Homo sapiens (Human)
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
MIGRISTENE

Approved Use

Prophylactic and curative treatment of migraine and headaches secondary other diseases.
Primary
Approved
8429
MIGRISTENE

Approved Use

Prophylactic and curative treatment of migraine and headaches secondary other diseases.
PubMed

PubMed

TitleDatePubMed
[Clinical use of dimetotiazine (8599RP)].
1967 Dec 10
[Resorption, excretion and biotransformation of 3-dimethylsulfamido-10-(2-dimethylaminopropyl)-phenothiazine (Dimetotiazine) in the rabbit and dog].
1967 Sep-Oct
Determination of isothipendyl or dimethothiazine with their sulphoxides using third- and fourth-derivatives spectroscopy on a diode-array spectrophotometer.
1990 Jul-Aug
Patents

Patents

07951398
20

Sample Use Guides

In Vivo Use Guide
Take 20-80 mg during the first day (2-4 tablets) and then - 40 mg/day (2 tablets) up to 3 months.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:17:23 GMT 2023
Edited
by admin
on Fri Dec 15 17:17:23 GMT 2023
Record UNII
1FTA475ZDB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FONAZINE
MI  
Common Name English
DIMETHOTHIAZINE
Common Name English
DIMETOTIAZINE
INN   WHO-DD  
INN  
Official Name English
dimetotiazine [INN]
Common Name English
Dimetotiazine [WHO-DD]
Common Name English
MIGRISTENE
Brand Name English
8599 R.P.
Code English
IL-6302
Code English
10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYLPHENOTHIAZINE-2-SULFONAMIDE
Systematic Name English
FONAZINE [MI]
Common Name English
PHENOTHIAZINE-2-SULFONAMIDE, 10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYL-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C66885
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
WHO-VATC QN02CX05
Created by admin on Fri Dec 15 17:17:24 GMT 2023 , Edited by admin on Fri Dec 15 17:17:24 GMT 2023
WHO-ATC N02CX05
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
Code System Code Type Description
WIKIPEDIA
DIMETOTIAZINE
Created by admin on Fri Dec 15 17:17:24 GMT 2023 , Edited by admin on Fri Dec 15 17:17:24 GMT 2023
PRIMARY
SMS_ID
100000082666
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
DRUG CENTRAL
1235
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
CAS
7456-24-8
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
RXCUI
50138
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C80770
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
PUBCHEM
3089
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
MERCK INDEX
m5528
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB08967
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
INN
2034
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
FDA UNII
1FTA475ZDB
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL346977
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
ECHA (EC/EINECS)
231-229-6
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
EVMPD
SUB07182MIG
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID6023076
Created by admin on Fri Dec 15 17:17:23 GMT 2023 , Edited by admin on Fri Dec 15 17:17:23 GMT 2023
PRIMARY
Related Record Type Details
Structure of FONAZINE MESYLATE
SALT/SOLVATE -> PARENT
Structure of FONAZINE, (R)-
ENANTIOMER -> RACEMATE
Structure of FONAZINE, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of FONAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966